Updated 02:01 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,868.50 -0.46% CL 85.14 -3.86% BTC 65,305.22 0.00%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,869 −0.46% BTC $65,305 VIX 22.91 +18.70% latest tape · as of 02:01 UTC
The Screen · Technology · Software - Application

Firefly Neuroscience Inc

AIFF · NASDAQ · USD · Market cap $18M · 17 employees

Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiologica…

FAIL · Does not pass the screen
0.94 USD

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price0.94 USD at the 13 Nov 2026 close
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Distribution ?
Screened · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price0.94 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-15Read Distribution0.94+0.0% to today Markdown gives way to Distribution after a 15% slide in 3 weeks
2026-10-28Read Markdown1.10-14.5% to today ✓Distribution gives way to Markdown first Markdown read since August
2026-10-21Read Distribution1.10-14.5% to today ✓Markup gives way to Distribution
2026-09-21Read Markup1.15-18.3% to today Markdown gives way to Markup after a 24% slide in 12 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Firefly Neuroscience Inc holds its Distribution at $0.94. Consolidating, no directional conviction, held for 15 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 15 days
Price at the screen$0.94
ValuationN/A trailing · N/A forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens, Shown in Full

Does not pass. Revenue purity

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load Excluded Below 33% Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 28.07% Below 49% Money owed to the company is 28.1% of assets, under the 49% limit. Pass
Revenue purity 7.79% Below 5% 7.8% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Firefly Neuroscience clears the business-activity screen. Where it falls short is income purity: around 8% of its income right now is non-operating interest income, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when AIFF's ethical verdict changes

Today AIFF does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

The Business, in Plain Words
The fundamentals · plain-English read
EPS, trailing-0.36
Revenue growth+1,027.9%growing very fast
Profit margin0.0%currently unprofitable
Return on equity-131.4%not currently earning a positive return on equity
FCF yield-53.59%
Current ratio1.82healthy short-term liquidity
Short interest, float0.05%
52-week range0.62 - 3.63
MoatNONE
Market cap$18M
Employees17

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

AIFF trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-15 Distribution · changed $0.94 +3.3% Entry 13

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-11-07 Markdown $0.91 -17.3% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 17.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-10-28 Markdown · changed $1.10 +0.0% Entry 11

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-10-21 Distribution · changed $1.10 -7.6% Entry 10

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-10-12 Markup $1.19 -3.3% Entry 9

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-10-02 Markup $1.23 +7.0% Entry 8

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-09-21 Markup · changed $1.15 +0.0% Entry 7

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-08-21 Markdown $1.15 +0.0% Entry 6

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-21 Markdown $1.15 -24.3% Entry 5

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 24.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-18 Markdown $1.52 +0.0% Entry 4

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in AIFF's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $1.80 -10.6% · $894 -10.6%
2 months $1.50 +7.3% · $1,073 +7.3%
3 months $1.74 -7.5% · $925 -7.5%
6 months $1.66 -3.0% · $970 -3.0%
1 year $3.31 -51.4% · $486 -51.4%
2 years $6.81 -76.4% · $236 -76.4%
3 years $12.60 -87.2% · $128 -87.2%
5 years $99.00 -98.4% · $16 -98.4%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever AIFF does next, these words stay.

Firefly Neuroscience Inc · AIFF · Distribution · $0.94
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.